1. Home
  2. OTLY vs CCCC Comparison

OTLY vs CCCC Comparison

Compare OTLY & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oatly Group AB

OTLY

Oatly Group AB

HOLD

Current Price

$11.89

Market Cap

454.4M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.01

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTLY
CCCC
Founded
1994
2015
Country
Sweden
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
454.4M
404.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
OTLY
CCCC
Price
$11.89
$3.01
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
★ $14.50
$12.20
AVG Volume (30 Days)
43.2K
★ 1.8M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 16.45
EPS
★ N/A
N/A
Revenue
N/A
★ $35,947,000.00
Revenue This Year
$7.91
N/A
Revenue Next Year
$5.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1.02
52 Week Low
$8.01
$1.69
52 Week High
$17.18
$5.17

Technical Indicators

Market Signals
Indicator
OTLY
CCCC
Relative Strength Index (RSI) 34.14 27.04
Support Level $10.01 $2.52
Resistance Level $12.53 $3.20
Average True Range (ATR) 0.49 0.17
MACD -0.15 -0.05
Stochastic Oscillator 2.30 16.37

Price Performance

Historical Comparison
OTLY
CCCC

About OTLY Oatly Group AB

Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: